Please login to the form below
amyloidosis
This page shows the latest amyloidosis news and features for those working in and with pharma, biotech and healthcare.
Alnylam’s RNAi therapeutic recommended by NICE for hereditary form of amyloidosis
The protein, which is called transthyretin (TTR), can become abnormal in ATTR amyloidosis and break apart into smaller pieces (amyloid). ... for standard of care Onpattro (patisiran), Alnylam’s earlier RNAi ATTRv amyloidosis therapy that is
Latest news
-
AstraZeneca and Ionis sign $3.6bn deal for eplontersen
The liver-targeted antisense therapy is in phase 3 trials for the treatment of transthyretin amyloidosis, a systemic, progressive and fatal condition. ... Eplontersen has the potential to halt the progression of TTR-mediated amyloidosis irrespective of
-
Pfizer's 2021 revenue predictions soar to $82bn
In addition to $13bn in sales from Comirnaty, anticoagulant Eliquis (apixaban) grew by 19% to $1.3bn, amyloidosis therapy Vyndaqel/Vyndamax (tafamidis) was up by 42% to $502m and Inlyta increased
-
AZ buys Caelum Biosciences for $500m
$350m. CAEL-101 is a potential first-in-class monoclonal antibody for the treatment of light chain (AL) amyloidosis. ... Standard treatment for AL amyloidosis is chemotherapy combined with thalidomide and/or steroids, which is effective but can kill the
-
Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn
Initially, Novo will focus on the clinical development of Prothena’s antibody PRX004 in ATTR cardiomyopathy, an underdiagnosed and potentially fatal form of ATTR amyloidosis. ... Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which
-
Alnylam scores EU approval for RNAi drug Givlaari
Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy.
More from news
Approximately 4 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
How telemonitoring can revolutionise the way we treat patients
Remote monitoring in practice. A prominent example of effective remote monitoring can be found in trials for ATTR cardiac amyloidosis (ATTR-CM).
-
20 for 2020 – Five pharma leaders to watch in 2020
Onpattro was approved to treat adults with the. destruction of nerves that results from a rare disease, hereditary transthyretin- mediated (hATTR) amyloidosis, and was launched with a $450, 000 per year ... pipeline. The company submitted its lumasiran
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
The drug is licensed to treat to adults with stage 1 or 2 polyneuropathy, the destruction of nerves that results from hereditary transthyretin- mediated (hATTR) amyloidosis, a rare, rapidly progressive, fatal ... The company is working with patient
-
Tough times for pharma in Portugal
spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis). ... The drug is to be granted marketing approval by the European Medicines Agency for the treatment of
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
What does the future hold for Light-chain Amyloidosis?
What is Light-chain (AL) Amyloidosis? Amyloidosis is a group of rare, serious conditions caused by the abnormal folding of amyloid proteins that build up in tissue throughout the body. ... enhance recognition of AL Amyloidosis itself and the therapies
-
ASCO 2015: What you missed in Chicago
Three monoclonal antibodies were presented on the last day of ASCO - two in multiple myeloma and one in amyloidosis.
-
Research Partnership
What does the future hold for Light-chain Amyloidosis?.
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
Wave Healthcare Communications
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
